Goldman Sachs Maintains Buy on Boston Scientific, Lowers Price Target to $84

Benzinga Newsdesk www.benzinga.com Negative 65.2%

Neg 65.2% Neu 0% Pos 0%

Goldman Sachs analyst David Roman maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $87 to $84.